Skip to main content Accessibility help
×
Home

Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole

  • C. DEVINE (a1), G. P. BRENNAN (a1), C. E. LANUSSE (a2), L. I. ALVAREZ (a2), A. TRUDGETT (a1), E. HOEY (a1) and I. FAIRWEATHER (a1)...

Summary

A study has been carried out to investigate whether the action of triclabendazole (TCBZ) against Fasciola hepatica is altered by inhibition of drug metabolism. The cytochrome P450 (CYP P450) system was inhibited using piperonyl butoxide (PB). The Oberon TCBZ-resistant and Cullompton TCBZ-susceptible isolates were used for these experiments. The CYP P450 system was inhibited by a 2 h pre-incubation in PB (100 μm). Flukes were then incubated for a further 22 h in NCTC medium containing either PB; PB+nicotinamide adenine dinucleotide phosphate (NADPH) (1 nm); PB+NADPH+TCBZ (15 μg/ml); or PB+NADPH+TCBZ.SO (15 μg/ml). Morphological changes resulting from drug treatment and following metabolic inhibition were assessed using scanning electron microscopy. After treatment with either TCBZ or TCBZ.SO alone, there was greater disruption to the TCBZ-susceptible than the resistant isolate. However, co-incubation with PB and TCBZ/TCBZ.SO lead to more severe surface changes to the TCBZ-resistant Oberon isolate than with each drug on its own. With the TCBZ-susceptible Cullompton isolate, there was limited potentiation of drug action, and only with TCBZ.SO. The results support the concept of altered drug metabolism in TCBZ-resistant flukes and this process may play a role in the development of drug resistance.

Copyright

Corresponding author

*Corresponding author: School of Biological Sciences, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland. Tel: +44 28 90972298. Fax: +44 28 90975877. E-mail: i.fairweather@qub.ac.uk

References

Hide All
Alvarez, L. I., Solana, H. D., Mottier, M. L., Virkel, G. L., Fairweather, I. and Lanusse, C. E. (2005). Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology 131, 501510.
Alvinerie, M., Dupuy, J., Eeckhoutte, C., Sutra, J. F. and Kerboeuf, D. (2001). In vitro metabolism of moxidectin in Haemonchus contortus adult stages. Parasitology Research 87, 702704.
Benchaoui, H. A. and McKellar, Q. A. (1996). Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. Journal of Pharmacy and Pharmacology 48, 753759.
Cvilink, V., Skálová, L., Szotáková, B., Lamka, J., Kostiainen, R. and Ketola, R. A. (2008). LC-MS-MS identification of albendazole and flubendazole metabolites formed ex vivo by Haemonchus contortus. Analytical and Bioanalytical Chemistry 391, 337343.
Cvilink, V., Szotáková, B., Krížová, V., Lamka, J. and Skálová, L. (2009). Phase I biotransformation of albendazole in lancet fluke (Dicrocoelium dendriticum). Research in Veterinary Science 86, 4955.
Devine, C., Brennan, G. P., Lanusse, C. E., Alvarez, L. I., Trudgett, A., Hoey, E. and Fairweather, I. (2009). Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology 136, 183192.
Fairweather, I. (2005). Triclabendazole: new skills to unravel an old(ish) enigma. Journal of Helminthology 79, 227234.
Fairweather, I. (2009). Triclabendazole progress report, 2005–2009: an advancement of learning? Journal of Helminthology 83, 139150.
Fairweather, I., Threadgold, L. T. and Hanna, R. E. B. (1999). Development of Fasciola hepatica in the mammalian host. In Fasciolosis (ed. Dalton, J. P.), pp. 47–111. CAB International, Wallingford, Oxon, UK.
Gotoh, O. (1998). Divergent structures of Caenorhabditis elegans cytochrome P450 genes suggest the frequent loss and gain of introns during the evolution of nematodes. Molecular Biology and Evolution 15, 14471459.
Gottschall, D. W., Theodorides, V. J. and Wang, R. (1990). The metabolism of benzimidazole anthelmintics. Parasitology Today 6, 115124.
Halferty, L., Brennan, G. P., Trudgett, A., Hoey, L. and Fairweather, I. (2009). The relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Veterinary Parasitology 159, 126138.
Hodgson, E. and Levi, P. (1998). Interactions of piperonyl butoxide with cytochrome P450. In Piperonyl Butoxide: The Insecticide Synergist (ed. Jones, D. G.), pp. 4153. Academic Press, San Diego, CA, USA.
Jones, D. G. (1998). Piperonyl Butoxide: The Insecticide Synergist. Academic Press, San Diego, CA, USA.
Kerboeuf, D., Soubieux, D., Guilluy, R., Brazier, J. L. and Riviere, J. L. (1995). In vivo metabolism of aminopyrine by the larvae of the helminth Heligmosomoides polygyrus. Parasitology Research 81, 302304.
Kotze, A. C. (1997). Cytochrome P450 monooxygenase activity in Haemonchus contortus (Nematoda). International Journal for Parasitology 27, 3340.
Kotze, A. C. (1999). Peroxide-supported in-vitro cytochrome P450 activities in Haemonchus contortus. International Journal for Parasitology 29, 389396.
Kotze, A. C. (2000). Oxidase activities in macrocyclic-resistant and -susceptible Haemonchus contortus. Journal of Parasitology 86, 873876.
Kotze, A. C., Dobson, R. J. and Chandler, D. (2006). Synergism of rotenone by piperonyl butoxide in Haemonchus contortus and Trichostrongylus colubriformis in vitro: potential for drug-synergism through inhibition of nematode oxidative detoxification pathways. Veterinary Parasitology 136, 275282.
McConville, M., Brennan, G. P., Flanagan, A., Hanna, R. E. B., Edgar, H. W. J., Castillo, R., Hernández-Campos, A. and Fairweather, I. (2009). Surface changes in adult Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Parasitology Research 105, 757767.
McKellar, Q. A., Gokbulut, C., Muzandu, K. and Benchaoui, H. (2002). Fenbendazole pharmacokinetics, metabolism, and potentiation in horses. Drug Metabolism and Disposition 30, 12301239.
Mottier, L., Alvarez, L., Ceballos, L. and Lanusse, C. (2006 a). Drug transport mechanisms in helminth parasites: passive diffusion of benzimidazole anthelmintics. Experimental Parasitology 113, 4957.
Mottier, L., Alvarez, L., Fairweather, I. and Lanusse, C. (2006 b). Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. Journal of Parasitology 92, 13551360.
Mottier, L., Virkel, G., Solana, H., Alvarez, L., Salles, J. and Lanusse, C. (2004). Triclabendazole biotransformation and comparative diffusion of the parent drug and its oxidized metabolites into Fasciola hepatica. Xenobiotica 34, 10431047.
Robinson, M. W., Lawson, J., Trudgett, A., Hoey, E. M. and Fairweather, I. (2004). The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitology Research 92, 205210.
Saeed, H. M., Mostafa, M. H., O'Connor, P. J., Rafferty, J. A. and Doenhoff, M. J. (2002). Evidence for the presence of active cytochrome P450 systems in Schistosoma mansoni and Schistosoma haematobium adult worms. FEBS Letters 519, 205209.
Sanchez, S., Small, J., Jones, D. G. and McKellar, Q. A. (2002). Plasma achiral and chiral pharmacokinetic behavior of intravenous oxfendazole co-administered with piperonyl butoxide in sheep. Journal of Veterinary Pharmacology and Therapeutics 25, 7–13.
Sanchez-Bruni, S. F. S., Fusé, L. A., Moreno, L., Saumell, C. A., Álvarez, L. I., Fiel, C., McKellar, Q. A. and Lanusse, C. E. (2005). Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Equine Veterinary Journal 37, 257262.
Solana, H. D., Rodriguez, J. A. and Lanusse, C. E. (2001). Comparative metabolism of albendazole and albendazole sulphoxide by different helminth parasites. Parasitology Research 87, 275280.
Solana, H., Scarcella, S., Virkel, G., Ceriani, C., Rodríguez, J. and Lanusse, C. (2009). Albendazole enantiomeric metabolism and binding to cytosolic proteins in the liver fluke Fasciola hepatica. Veterinary Research Communications 33, 163173.
Toner, E., McConvery, F., Brennan, G. P., Meaney, M. and Fairweather, I. (2009). A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology 136, 523535.
Velík, J., Baliharová, V., Fink-Gremmels, J., Bull, S., Lamka, J. and Skálová, L. (2004). Benzimidazole drugs and modulation of biotransformation enzymes. Research in Veterinary Science 76, 95–108.
Virkel, G., Lifschitz, A., Sallovitz, J., Ballent, M., Scarcella, S. and Lanusse, C. (2009). Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. Journal of Veterinary Pharmacology and Therapeutics 32, 7986.
Walker, S. M., McKinstry, B., Boray, J. C., Brennan, G. P., Trudgett, A., Hoey, E. M., Fletcher, H. and Fairweather, I. (2004). Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitology Research 94, 427438.

Keywords

Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole

  • C. DEVINE (a1), G. P. BRENNAN (a1), C. E. LANUSSE (a2), L. I. ALVAREZ (a2), A. TRUDGETT (a1), E. HOEY (a1) and I. FAIRWEATHER (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed